Project Grant HT94252510270
Award Date
6/1/25
Completion Date
5/31/29
Dollars Obligated
$1M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Great Britain, United Kingdom
Similar Awards
This federal Project Grant award, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program, supports advanced biomedical research focused on transforming healthcare for military service members and the broader public. The $345,664 award, effective December 1, 2024 through November 30, 2026, will fund research by Royal Holloway and Bedford New College in the United Kingdom to enhance immune protection for an...
The federal Project Grant award, titled "EVIDENCE-BASED PREDICTION OF CARDIOVASCULAR RISK IN IMMUNE-MEDIATED INFLAMMATORY DISEASE", is funded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The $2,377,839 award was granted to The Regents of the University of California, San Francisco on June 1, 2025, with a performance period ending on May 31, 2029. The project aims to develop innovative, AI-based diagnostic tools for predicting...
The U.S. Defense Health Agency awarded King's College London a $1,712,517 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to identify molecular predictors of risk and validate the evolution of ductal carcinoma in situ (DCIS) over a 4-year period ending on September 29, 2027. As the prime awardee, King's College London will leverage its expertise in biomedical research to advance the scientific understanding of breast cancer progression. This award supports...
This federal Project Grant award of $299,999.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) is funding research at the Institute of Cancer Research: Royal Cancer Hospital (The) in the United Kingdom. The award aims to enhance the efficacy of BH3 mimetics, a class of cancer therapeutic drugs, to induce apoptosis (programmed cell death) in lethal prostate cancer. The performance period for this award is June 1, 2024 through May 31, 2026. As a...
The federal Project Grant award of $254,153.00 was made on March 1, 2025 by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The award supports advanced biomedical research focused on the relationship between microplastics and prostate cancer at New York University School of Medicine, a prominent academic medical center and research institution. The funding will enable researchers to investigate innovative approaches to disease prevention,...
The federal Project Grant award of $1,008,313.00 was provided by the Defense Health Agency through the Military Medical Research and Development program (CFDA 12.420) to The Regents of the University of California, San Francisco (UCSF). The grant, awarded on September 1, 2024, supports advanced biomedical research initiatives focused on transforming healthcare for military service members and the broader public. The award will fund innovative scientific investigations spanning basic, applied,...
The University of Cambridge received a $824,548 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research on understanding the role of hypoxia in vasculogenic mimicry, response to therapy, and metastasis. This 3-year grant awarded on May 1, 2024 will support basic, translational, and clinical research to advance scientific understanding and develop new treatments in areas such as cancer, neurological...
The federal Project Grant award in the amount of $499,999.00, awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), funds research by the Institute of Cancer Research: Royal Cancer Hospital (The) to study the interplay of molecular and spatial architectures with clinical states in prostate cancer. The research project aims to make discoveries that defeat cancer through innovative biomedical research. As a subawardee, the Institute of...
The federal Project Grant award, valued at $1,898,000.00, was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant is supporting the development of a rapid, fieldable nanopore sequencing-based prognostic and diagnostic assay to advance clinical management decision-making. The primary awardee, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., will leverage this funding over a 3-year period from...
The federal Project Grant award of $422,299.00 was provided by the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) program. The grant, awarded on February 1, 2025, supports research by Texas A&M University System Health Science Center (TAMU HSC) to study inhibiting renal lymphatic expansion to mitigate nephrotic syndrome. The research aims to develop innovative medical solutions addressing complex healthcare challenges relevant to military...